DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
This strategic decision will unlock significant value for our scientific and industrial products business
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
